新型聚乙二醇干扰素治疗慢性病毒性肝炎

StephenW

新型聚乙二醇干扰素治疗慢性病毒性肝炎

    2022 年 5 月病毒 14(6):1128

    DOI: 10.3390/v14061128

    许可证CC BY 4.0

    Yi-Wen HuangYi-Wen HuangAlbert QinChan-Yen TsaiPei-Jer ChenPei-Jer Chen


    2022 年 3 月


抽象的
Ropeginterferon alfa-2b 是一种新型单聚乙二醇化超长效干扰素，正在开发用于治疗骨髓增生性肿瘤 (MPN) 和慢性病毒性肝炎。与具有多种异构体且每周给药的常规聚乙二醇化干扰素产品相比，它具有良好的药代动力学特征和较低频率的给药方案，即每两到四周一次。它被批准用于真性红细胞增多症（一种 MPN）的长期治疗，并已被纳入该适应症的 NCCN 临床实践指南。在多项临床研究中，Ropeginterferon alfa-2b 已证明有效，并显示出治疗慢性病毒性肝炎的良好安全性。在本文中，我们回顾了其药代动力学和现有临床数据，并建议每两周给药一次的ropeginterferon alfa-2b可以作为慢性病毒性肝炎（包括慢性乙型、丙型和丁型肝炎）患者的新治疗选择。

StephenW

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

    May 2022Viruses 14(6):1128

    DOI: 10.3390/v14061128

    LicenseCC BY 4.0

    Yi-Wen HuangYi-Wen HuangAlbert QinChan-Yen TsaiPei-Jer ChenPei-Jer Chen


    March 2022


Abstract
Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis. It has a favorable pharmacokinetic profile and less frequent dosing schedule, i.e., once every two to four weeks, compared to conventional pegylated interferon products, which have multiple isomers and are administered weekly. It was approved for the long-term treatment of polycythemia vera, an MPN, and has been included in the NCCN clinical practice guidelines for this indication. Ropeginterferon alfa-2b has demonstrated efficacy and showed a favorable safety profile for the treatment of chronic viral hepatitis in several clinical studies. In this article, we review its pharmacokinetics and available clinical data and suggest that ropeginterferon alfa-2b administered once every two weeks can serve as a new treatment option for patients with chronic viral hepatitis, including chronic hepatitis B, C, and D.

lancas

如果两周一次的确可以减少很多患者的痛苦，但不知道是临床几期和数据如何

pppq123

牛，不知道临床数据和传统干扰素有没有优势

油腻大叔

能减少禁忌症就好了。

齐欢畅